Systemic and intracerebroventricular administration of BDNF lowered blood glucose, decreased body weight, reduced hepatomegaly, and liver glycogen content in experimental animals with obesity and diabetes (403). Here, BDNF is linked to obesity due to melanocortin 4 receptor deficiency.